CSS
REGN icon

Cubist Systematic Strategies’s Regeneron Pharmaceuticals REGN Stock Holding History

Cubist Systematic Strategies’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.47M Sell
4,400
-8,700
-66% -$4.92M 0.01% 1433
2025
Q2 		$6.88M Sell
13,100
-200
-2% -$112K 0.03% 823
2025
Q1 		$8.44M Sell
13,300
-5,000
-27% -$3.44M 0.05% 575
2024
Q4 		$13M Buy
18,300
+15,000
+455% +$12.6M 0.08% 354
2024
Q3 		$3.47M Buy
+3,300
New +$3.67M 0.02% 1074
2024
Q2 		– Sell
-6,100
Closed -$5.87M – 3838
2024
Q1 		$5.87M Sell
6,100
-12,200
-67% -$11.6M 0.03% 861
2023
Q4 		$16.1M Sell
18,300
-1,200
-6% -$988K 0.1% 229
2023
Q3 		$16M Buy
19,500
+800
+4% +$629K 0.12% 177
2023
Q2 		$13.4M Buy
18,700
+3,200
+21% +$2.47M 0.09% 286
2023
Q1 		$12.7M Buy
15,500
+9,300
+150% +$7.01M 0.08% 339
2022
Q4 		$4.47M Buy
+6,200
New +$4.57M 0.03% 1119

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cubist Systematic Strategies's REGN Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q3 2025, selling an estimated $8.86M and leaving 79,264 shares worth $44.6M. The position accounts for 0.21% of the portfolio, ranked #90.

Cubist Systematic Strategies first reported a position in REGN in Q2 2014 and has held it in 41 quarters since. The position peaked at $49.8M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Cubist Systematic Strategies held 79,264 shares of Regeneron Pharmaceuticals worth $44.6M as of Q3 2025.
  • Cubist Systematic Strategies sold 15,678 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $8.86M.
  • Regeneron Pharmaceuticals made up 0.21% of Cubist Systematic Strategies's portfolio in Q3 2025, its #90 holding.
  • Cubist Systematic Strategies first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 41 quarters since.
  • Cubist Systematic Strategies's Regeneron Pharmaceuticals position peaked at $49.8M in Q2 2025.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.